Introduction
Acute myeloid leukemia (AML) is characterized by an accumulation of cells of varying maturity in the bone marrow and blood, leading eventually to bone marrow failure (Appelbaum et al., 2001) . AML is generally considered to be caused by an accumulation of oncogenic mutations in hematopoietic stem/progenitor cells (HSC/HPC). Some of the most common mutations associated with AML are activating mutation of ras gene family members. Specifically, activating mutations in N-or K-ras occur in approximately 20% of cases of AML and are associated with a poor prognosis (Neubauer et al., 1994a, b) .
The precise role of ras mutations in myeloid leukemogenesis is not known. The expression of activated ras in human HSC/HPCs induces lineage dysplasia in vitro and drives myeloid differentiation in nonobese diabetic/severe confined immunodeficient (NOD/SCID) mouse models (Darley et al., 1997; Shen et al., 2004) . In myeloid cell lines, it has been shown that activated ras genes may induce either a phenotype characteristic of differentiation or of oncogenic transformation in a cell-type-specific manner (Maher et al., 1996; Delgado et al., 2000; Matsumura et al., 2000; Dolnikov et al., 2003a) . Specifically, it has been shown that expression of H-or N-ras in U937 cells induces growth suppression, partial monocytic differentiation and apoptosis (Maher et al., 1996) . In these cells, rasinduced growth suppression/apoptosis is dependent upon upregulation of the tumor-suppressor gene interferon regulatory factor-1 (IRF-1) (Passioura et al., 2005) . Thus, somewhat paradoxically, it appears that one of the primary effects of ras oncogenes in hematopoietic cells is suppression of proliferation and induction of myeloid differentiation.
The expression of activated ras in murine HSC/HPCs is sufficient to induce leukemia with a long latency (MacKenzie et al., 1999) , suggesting that additional mutations are required for ras-mediated leukemogenesis. Since ras genes inhibit the proliferation of HPCs and some myeloid cell lines, mutations that abrogate this 'ras-induced' growth suppression are likely candidates for such additional mutations. In order to identify candidate genetic targets of such mutations, the present study used U937 myeloid cells as the basis of a genetic screen. The growth suppression induced by a mutant Nras gene (G to R mutation at codon 13; N-rasG13R) in U937 cells was used as the basis to screen a retroviral cDNA library for genes that prevent N-rasG13R-induced growth suppression, and thus may cooperate with mutant N-ras to induce oncogenic transformation. This screen identified the gene for the transcription factor interferon regulatory factor-2 (IRF-2) and two independent clones of a truncated form of the PP2135 gene (t-PP2135), which has no known function. Further experiments showed that over-expression of IRF-2, but not t-PP2135, in U937 cells was sufficient to 'rescue' U937 cells from N-ras-induced growth suppression. These results demonstrate that IRF-2 can prevent activated N-ras-induced growth suppression of myeloid cells, and suggest that IRF-2 overexpression may cooperate with N-ras mutation in myeloid leukemogenesis.
Results

Library screening
In order to generate a retroviral cDNA library of high complexity and titer, retrovirus generated transiently from producer cell lines of different tropism (amphotropic Amphopak-293 cells and ecotropic C-Cre cells) was used to superinfect PG13 cells. Retrovirus from these PG13 cells was subsequently used to infect U937 cells. The efficiency of gene transfer to both PG13 and U937 cells was estimated by spiking the retroviral library 1 : 10 with the enhanced green fluorescent protein (EGFP) expressing plasmid pLIB-EGFP ( Figure 1a) . A schematic illustration of virus generation and a single round of screening is provided in Figure 1b .
Simultaneous infection of PG13 cells was performed using virus containing medium (VCM) transiently produced by calcium phosphate-mediated transfection of Amphopak-293 and C-Cre cells. The percentage of EGFP-positive PG13 cells was 11.5% (Figure 2a) , giving an estimated infection efficiency over 100% (since the EGFP plasmid was present at a ratio of 1 : 10). This indicates that superinfection of the PG13 cells had occurred, and that these cells expressed multiple copies of the vector per cell. VCM was harvested from this 'superinfected producer' and used to infect 10 7 U937 cells. The proportion of EGFP-positive U937 cells was 1.3% (Figure 2b ). Since the library containing plasmid was spiked 1 : 10 with the EGFP plasmid, this gave an estimated infection efficiency of 13%. Since 10 7 target U937 cells were infected, this correlates to infection of 1.3 Â 10 6 U937 cells. To confirm that there was no substantial loss of complexity, PCR using retrovirusspecific primers was performed on both the PG13-based library producer cell line and on U937 cells infected with virus derived from it ( Figure 2c ). The resultant smear between 0.5 and 2 kb with a single pLIB-EGFP band at 0.7 kb indicated that there had been no substantial loss in complexity.
The U937 cells previously transduced (from above) with the library were next transduced by retroviral gene transfer with the L9NrIGFP construct (Figure 1 ), which expresses both an activated N-rasG13R and the yellowshifted green fluorescent protein topaz variant (GFPtpz) reporter gene. Cells were sorted for the expression of GFPtpz but excluding EGFP in order to recover cells expressing N-rasG13R. After the initial sort, this culture was passaged for 8 days, during which time the proportion of cells expressing GFPtpz decreased from approximately 40% to approximately 30%, as a consequence of growth suppression in N-rasG13R/ GFPtpz-expressing cells (Figure 3a ). This culture was sorted again for GFPtpz expression yielding a culture of >90% GFPtpz-postive cells. After a further Retrovirus-specific PCR was performed to recover the library inserts from the initial screen. This PCR product was used to generate an enriched library by subcloning Figure 2 Transduction of U937 cells with a cDNA library. A 10 : 1 mixture of retroviral cDNA library in the pLIB vector and pLIB-EGFP was introduced into Amphopak-293 and C-Cre cells by calcium phosphate transfection, and transiently generated virus from these cells was used to infect PG13 cells. GaLV-pseudotyped virus from this PG13 culture was used to infect 10 7 U937 cells. FACS analysis of the PG13 and U937 cultures (a and b) showing the proportion of LIB-EGFP-infected cells. Retrovirus-specific PCR performed using DNA extracted from these two cultures or the original 10 : 1 plasmid mixture (c) showed library complexity at each stage Figure 3 Screening of a retroviral cDNA library for genes that prevent N-rasG13R-induced growth suppression of U937 cells. Both parental U937 cells and U937 cells infected with the retroviral cDNA library/EGFP mixture were transduced with the L9NrIGFP vector by retroviral infection. GFPtpz-expressing cells were isolated from untransduced and EGFP-expressing cells by FACS. This yielded cultures approximately 40 and 52% GFPtpz positive for the library transduced and control samples, respectively (a, point 1). The library-transduced and L9NrIGFP alone-transduced cultures were passaged for 7 days (a, region 2) and sorted again to derive cultures approximately 90% for GFPtpz expression (a, point 3). After a further 12 days (a, region 4), the GFPtpz expression of both cultures appeared to reach stability at a level approximately 60%. Library inserts were recovered by retrovirus-specific PCR, cloned to generate an enriched library and reintroduced into U937 cells by retroviral infection. Both parental U937 cells and U937 cells infected with the enriched retroviral cDNA library were transduced with the L9NrIGFP vector by retroviral infection. GFPtpzexpressing cells were isolated from untransduced cells by flow cytometry yielding cultures between 50 and 60% positive for GFPtpz expression (b, point 1). Both cultures were passaged for 16 days (b, region 2), during which time the proportion of GFPtpzexpressing cells decreased to approximately 20%. The cultures were sorted again to derive cultures approximately 60% for GFPtpz expression (b, point 3). After a further 8 days (b, region 4), the GFPtpz expression of the library-transduced culture appeared stable at a level of approximately 60%. In contrast, the proportion of GFPtpz-expressing cells in the control culture decreased to approximately 40% in this time IRF-2 inhibits N-ras-induced growth suppression T Passioura et al the recovered library into the pLIB backbone using two cloning strategies to minimize the possibility of unintended digestion of library inserts (see Materials and methods). This enriched library was delivered into U937 cells by retroviral gene transfer (using the superinfection of PG13 cells technique outlined above), and these cells were challenged again with the L9NrIGFP construct. Sorting for GFPtpz was performed, yielding a population that was approximately 60% GFPtpz positive (Figure 3b ). After 16 days in culture, this proportion had decreased to approximately 23% (Figure 3b ). GFPtpz-positive cells were isolated by flow cytometry to yield a population that was approximately 60% GFPtpz positive. After a further 8 days in culture, this population retained a relatively stable GFPtpz-positive population (decreasing to approximately 57% GFPtpz positive in this time). In contrast, cells transduced with L9NrIGFP alone continued to exhibit N-rasG13R-induced growth suppression, with the proportion of GFPtpz-positive cells decreasing from 55 to 37% over this 8-day period ( Figure 3b ).
Retrovirus-specific PCR was performed on genomic DNA from this doubly enriched library screen and the inserts were cloned. In all, 20 of these clones were sequenced. In total, five distinct sequences were identified (Table 1) . One of these was an artifact of the PCR recovery procedure (as evidenced by detectable false primer binding sites at the ends of the recovered insertdata not shown). A second was the N-rasG13R gene, which was presumably amplified from a recombinant L9NrIGFP vector (since this vector also contains binding sites for the retrovirus-specific primers used, but the full-length L9NrIGFP vector is too long to be amplified by the PCR protocol used). Of the remaining three, one was a full-length cDNA of the IRF-2 gene, and the other two inserts were independent clones of a truncated fragment of a gene of the immunoglobulin superfamily with no known function (Genbank Accession no. BC020568). This gene does not have an official symbol or name but has been assigned the interim symbol PP2135 (other names: FLJ00041, GI24 and GVPT730). In the present study, the truncated form is designated t-PP2135.
Effect of IRF-2 and t-PP2135 overexpression on N-rasG13R-induced growth suppression in U937 cells
To confirm that t-PP2135 and IRF-2 were each capable of rescuing U937 cells from N-rasG13R-induced growth suppression, the smaller of the two t-PP2135 fragments and the IRF-2 cDNA were separately cloned into the LXIN retroviral backbone (generating the vectors pLtPIN and pLIRF2IN, respectively - Figure 1 ) and introduced into U937 cells following transient retrovirus production (in Amphopak-293 cells) and infection. Stable populations of t-PP2135-or IRF-2-expressing cells were established by G418 selection (500 mg/ml) and cells were analysed by Northern analysis to confirm expression of the retroviral construct (Figure 4 ). The expression of each vector was detectable in all cases. However, the IRF-2 expression vector appeared to be expressed at markedly lower levels (approximately 20-fold lower as assessed by ImageQuantt software) than either the control or t-PP2135 expression vectors. This may indicate that high levels of IRF-2 expression exert a negative effect upon cell proliferation or survival. In this regard, it is relevant that overexpression of IRF-2 has been shown to promote cell death in certain myeloid cell lines (Xie et al., 2002) .
U937 cells expressing LXIN, LtPIN or LIRF2IN were transduced with the L9NrIGFP vector or the L9IGFP control vector. U937 cells expressing IRF-2 were found to be partially resistant to N-rasG13R-induced growth suppression as evidenced by the relative stability of the N-rasG13R/GFP expressing population In all, 20 recovered inserts were sequenced (one sequencing reaction failed) Figure 4 Northern analysis of U937 cells transduced with IRF-2 and t-PP2135 expression vectors. RNA extracted from U937 cells transduced with the LXIN, LIRF2IN or LtPIN vectors was used for Northern analysis to confirm expression of the respective vectors. Probes were specific for IRF-2, PP2135 or the LXIN backbone. RNA extracted from untransduced U937 cells was used as a negative control. A probe for b-actin was used as a loading control IRF-2 inhibits N-ras-induced growth suppression T Passioura et al ( Figure 5a ). In contrast, U937 cells expressing t-PP2135 appeared not to be resistant to the growth inhibitory effects of N-rasG13R and demonstrated growth suppression of similar magnitude to cells expressing the LXIN control vector (Figure 5b ). This suggests that unlike IRF-2, t-PP2135 does not cooperate with N-rasG13R during oncogenic transformation of U937 cells. Interestingly, however, cells expressing t-PP2135 demonstrated significantly higher proportions of GFPtpz-positive cells when infected with both the GFPtpz control and N-rasG13R vectors than did cells expressing the LXIN control (32% increase in infection by L9IGFP, 35% increase in infection by L9NrIGFP, Po0.005 for both). This suggests that t-PP2135 may act to enhance the susceptibility of U937 cells to retroviral infection; this would provide an explanation for the selective advantage apparently conferred by t-PP2135 in this screen.
To confirm that t-PP2135 did not inhibit N-rasG13R-induced growth suppression of U937 cells, purified populations of U937 cells expressing LtPIN and L9NrIGFP (or the relevant control vectors) were isolated by flow cytometry. The growth of these cells was assessed in semisolid media (Figure 5d ). The suppression of colony formation by N-rasG13R was equally strong in U937 cells expressing LtPIN as it was in cells expressing the LXIN control, indicating that t-PP2135 did not inhibit N-rasG13R-induced growth suppression in these cells. Since the objective of this screen was to identify genetic modulators of N-rasG13R-induced growth suppression, investigation of the t-PP2135 gene was not continued further.
To further investigate the ability of IRF-2 to inhibit N-rasG13R-induced growth suppression in U937 cells, purified populations of U937 cells expressing LXIN and L9IGFP, LXIN and L9NrIGFP, LIRF2IN and L9IGFP, or LIRF2IN and L9NrIGFP were generated by G418 selection and fluorescence-activated cell sorting (FACS) for GFPtpz-expressing cells. In all cases, the final population was greater than 85% GFPtpz positive (data not shown). The proliferative rate of these purified populations was assessed in liquid culture. Cells expressing N-rasG13R alone (L9NrIGFP and LXIN) showed marked growth suppression relative to cells expressing the GFPtpz control vector (L9IGFP and LXIN, or L9IGFP and LIRF2IN) (Figure 5e ). Cells expressing N-rasG13R and IRF-2 (L9NrIGFP and LIRF2IN) demonstrated a proliferative rate that was higher than that of cells expressing N-rasG13R alone, but lower than cells expressing the GFPtpz control vector.
Colony assays in methylcellulose media were performed to assess the effect of IRF-2 on colony formation in GFPtpz control vector and N-rasG13R-expressing cells. The expression of N-rasG13R caused a marked reduction in colony formation of U937 cells in semisolid media (Figure 5c ). Colony formation was restored in cells expressing both N-rasG13R and IRF-2. The expression of IRF-2 alone had no effect upon colony formation of U937 cells in semisolid media, indicating that this effect was specific to the N-rasG13R-induced phenotype.
Mechanism of IRF-2-mediated tumor progression
We had previously shown that the N-rasG13R-induced growth suppression of U937 cells was dependent upon IRF-1 upregulation (Passioura et al., 2005) . IRF-2 has been shown to antagonize IRF-1-mediated transcriptional activation (Harada et al., 1989; Coccia et al., 1999) . This suggests that IRF-2 expression protects U937 cells from N-rasG13R-induced growth suppression by inhibiting IRF-1-mediated transcription. To assess the validity of this model, Northern analysis was performed using RNA extracted from the four FACSsorted and G418-resistant cultures expressing LIRF2IN and L9NrIGFP (or relevant control vectors) described above ( Figure 6 ). Cells expressing N-rasG13R demonstrated marked induction of both IRF-1 and p21
CIP1WAF1
. This increase in IRF-1 expression appeared to be independent of the level of IRF-2 expression. In contrast, ectopic IRF-2 expression appeared to completely abrogate upregulation of p21 CIP1/WAF1 in response to N-rasG13R. These findings are consistent with a model of N-rasG13R-induced growth suppression mediated by IRF-1 transcriptional activation, in which IRF-2 prevents growth suppression by inhibiting the expression of IRF-1-responsive genes.
N-rasG13R both induces apoptosis and suppresses proliferation in U937 cells (Passioura et al., 2005) . Upregulation of p21 CIP1/WAF1 is known to inhibit proliferation but not to induce apoptosis. In fact, high p21 CIP1/WAF1 levels have been shown to prevent apoptosis (Dolnikov et al., 2000) . Since N-rasG13R-induced both growth suppression and apoptosis in U937 cells, it seemed likely that N-rasG13R induced upregulation of IRF-1 in U937 cells led to transcription of proapoptotic genes, in addition to upregulating p21 CIP1/WAF1 . Since there appears to be some functional overlap between Figure 6 Expression of IRF-1, IRF-2, p21 CIP1WAF1 and pml in response to N-rasG13R. Northern analysis was performed using RNA from U937 cells expressing the LIRF2IN and/or L9NrIGFP vectors (or the control vectors LXIN and L9IGFP, respectively). Cells expressing N-rasG13R demonstrated upregulation of IRF-1, pml and p21 CIP1/WAF1 . Overexpression of IRF-2 did not affect N-rasG13R-induced upregulation of IRF-1, but abrogated N-rasG13R-induced upregulation of both p21 CIP1/WAF1 and pml. b-actin was used as a loading control IRF-2 inhibits N-ras-induced growth suppression T Passioura et al IRF-1 and p53 (Tanaka et al., 1996; Lallemand et al., 1997; Lallemand et al., 2002) , the proapoptotic pml gene (which is induced by activated ras in a p53-dependent manner in primary human fibroblasts) appeared a good candidate for such an IRF-1-inducible, proapoptotic gene. Assessment of pml expression in U937 cells demonstrated N-rasG13R-induced pml upregulation, which could be prevented by IRF-2 expression ( Figure 6 ). This suggests that, in p53 deficient U937 cells, pml may be upregulated by IRF-1 during N-rasG13R-induced growth suppression, providing a potential mechanism for IRF-1-dependent N-rasG13R-induced apoptosis in U937 cells.
Discussion
The aim of the present study was to identify genes capable (when expressed constitutively) of preventing N-rasG13R-induced growth suppression of myeloid cells. The genetic screening technique used putatively identified the IRF-2 and t-PP2135 genes as modulators of N-rasG13R-induced growth suppression. Further experiments demonstrated that IRF-2, but not t-PP2135, inhibited N-rasG13R-induced growth suppression of U937 cells in liquid culture and in colony assays. These results show that IRF-2 is capable of preventing N-rasG13R-induced growth suppression of myeloid leukemic cells. Since the two clones of the truncated PP2135 gene were of different lengths, they must have been derived independently. The chance of two independent clones being recovered by chance in this screen, even if this gene was over-represented in the initial library, are exceedingly low. Therefore, even though this gene did not appear to rescue U937 cells from N-rasG13R-induced growth suppression, it is likely that some selective advantage was conferred by the t-PP2135 cDNA. To the best of our knowledge, only three publications have made reference to the PP2135 gene (Strausberg et al., 2002; Clark et al., 2003; Ota et al., 2004) . Two of these were large-scale sequencing of human cDNAs, which provided no functional information about the PP2135 gene (Strausberg et al., 2002; Ota et al., 2004) . The third was an identification of human secreted and transmembrane proteins, in which computer modeling suggested that PP2135 was likely to be a transmembrane protein (Clark et al., 2003) . Thus, the function of this gene is unknown. When subcloned and introduced into U937 cells, t-PP2135 did not show any ability to reduce N-rasG13R growth suppression. However, U937 cells ectopically expressing t-PP2135 appeared to demonstrate a greater susceptibility to retroviral infection. Since productive retroviral infection is dependent upon passage of the target cells through the cell cycle (Miller et al., 1990; Dolnikov et al., 2003b) , this increase in susceptibility to infection suggested that t-PP2135 may act to increase the rate of cellular proliferation, providing a mechanism for a selective advantage. However, further experiments are required to determine the function of this gene.
We had previously shown that N-rasG13R-induced growth suppression of U937 cells was dependent upon upregulation of IRF-1 and was associated with consequent upregulation of the IRF-1 target and cyclindependent kinase inhibitor p21 CIP1/WAF1 (Passioura et al., 2005) . This suggested a model for N-rasG13R-induced growth suppression in which N-rasG13R expression induced IRF-1 expression leading in turn to p21 CIP1/WAF1 upregulation and consequent growth arrest. IRF-2 generally antagonizes IRF-1-mediated transcription (Harada et al., 1989; Tanaka et al., 1994; Coccia et al., 1999; Rubinstein et al., 2000) . Both proteins bind to the same DNA promoter elements (interferon regulatory factor-element, IRF-E; interferon-stimulated response element, ISRE) (Harada et al., 1989; Xi and Blanck, 2003) . Binding of IRF-1 to these elements promotes transcription (Tanaka et al., 1996; Coccia et al., 1999) , whereas binding of IRF-2 to these elements generally represses transcription (Harada et al., 1989; Tanaka et al., 1994; Coccia et al., 1999) . Specifically, IRF-2 has been shown to suppress p21 CIP1/WAF1 expression in U937 cells (Coccia et al., 1999; Rubinstein et al., 2000) . Thus, the findings of the present study (overexpression of IRF-2 inhibits N-rasG13R-induced growth suppression) support this 'IRF-1-dependent' model of ras-induced growth suppression of myeloid cells.
The inactivation of IRF-1, through chromosomal deletion or accelerated exon skipping, occurs relatively frequently in AML (Willman et al., 1993; Harada et al., 1994) . Moreover, functional inactivation of IRF-1, as a result of high constitutive IRF-2 expression (with no detectable inactivation of IRF-1) has also been observed in approximately 70% of cases of AML (Preisler et al., 2001) . Since IRF-1 appears to mediate a tumorsuppressive response to dysregulated ras signaling, it seems likely that ras mutations and IRF-1 inactivation cooperate during myeloid leukemogenesis. Reinstatement of the IRF-1-mediated tumor suppressive response to ras genes may constitute a useful therapeutic strategy for treatment of AML harboring a ras mutation. In this regard, IRF-2 is a possible therapeutic target, since inhibition of IRF-2 activity may restore the IRF-1 : IRF-2 ratio and allow IRF-1-mediated tumor suppression.
As in primary human fibroblasts, expression of mutant ras genes in primary human CD34 þ HSC/ HPCs causes upregulation of tumor-suppressor genes (our unpublished data). The expression of mutant ras genes in murine HSC/HPCs induces myeloid malignancies with long latency, suggesting that additional mutations (which presumably inactivate tumor-suppressive pathways) are required for leukemogenesis (MacKenzie et al., 1999; Chan et al., 2004) . The inactivation of IRF-1 (either through suppressing IRF-1 or increasing IRF-2 expression) prevents N-ras-associated growth suppression of myeloid cells (Passioura et al., 2005 and the present study). Thus, IRF-1-inactivating mutations (including those that lead to dysregulated expression of IRF-2) are likely candidates for additional mutations required for N-ras-induced leukemogenesis in mice. It should be noted that while the present study supports IRF-2 inhibits N-ras-induced growth suppression T Passioura et al this hypothesis, it does not conclusively demonstrate that IRF-2 overexpression and N-ras mutation cooperate during leukemogenesis in vivo. Such a finding would require experiments involving simultaneous expression of IRF-2 and a mutant N-ras in murine HSC/ HPCs transplanted into a syngeneic host.
Similar to U937 myeloid cells, primary human fibroblasts demonstrate a growth suppressed phenotype (senescence) in response to the expression of activated ras genes (Serrano et al., 1997) . In those fibroblast cells, the growth suppressive pathways downstream of Ras have been extensively characterized; Ras-induced senescence of primary fibroblasts is mediated by the INK4a, ARF, pml and p53 tumor-suppressor genes and is associated with the upregulation of p21 CIP1/WAF1 in a p53-dependent manner (Serrano et al., 1997; Ferbeyre et al., 2000; Pearson et al., 2000) . Since U937 cells do not express active p53 (Shiohara et al., 1996) , the Ras-p53-p21
pathway active in primary fibroblasts cannot be active in U937 cells. In contrast to fibroblasts, ras-associated upregulation of p21 CIP1/WAF1 in myeloid cells appears to be dependent upon IRF-1 rather than p53 (Passioura et al., 2005) . Thus, it appears that in p53-negative U937 myeloid cells, the lack of p53 expression is compensated for by IRF-1.
During ras-induced senescence of fibroblasts, upregulation of pml is dependent upon the expression of active p53 (de Stanchina et al., 2004) . In the present study, we have shown that pml expression is induced by NrasG13R in U937 cells (which are p53 negative), and that this induction could be repressed by IRF-2. The pml promoter contains an ISRE, and interferon treatment of cells induces pml expression (Stadler et al., 1995) . Thus, it is likely that pml is a direct IRF-1 target gene, providing a mechanism for induction of pml expression in response to N-rasG13R in p53-negative U937 cells.
The results presented in this work support the existence of an IRF-1-dependent tumor-suppressive pathway acting to prevent N-rasG13R-induced oncogenesis in myeloid cells. Similar to the p53-dependent tumor-suppressive pathway activated by ras genes in primary fibroblasts, this pathway appears to result in the upregulation of both p21 CIP1/WAF1 and pml, suggesting that IRF-1 may be compensating for the lack of tumorsuppressive pathways in these p53-deficient cells. The finding that IRF-2 is capable of preventing N-rasG13R-induced growth suppression of myeloid cells is likely to assist in the development of murine models of human AML, and IRF-2 itself may constitute a therapeutic target.
Materials and methods
General cell maintenance conditions and FACS
The PG13, C-Cre and Amphopak-293 lines were maintained in Dulbecco's modified eagle's medium (GIBCO, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS, GIBCO BRL) and 0.2 mM glutamine. Human leukemic U937 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium (GIBCO BRL) supplemented with 10% FCS (GIBCO BRL) and 0.2 mM glutamine. Isolation of cells and flow cytometric analysis was performed using a FACScalibur flow cytometer (Becton Dickinson).
Proliferation assays
For assessment of growth suppression in cells expressing the L9NrIGFP vector, depletion of GFPtpz-expressing cells was taken as a measure of growth suppression. Cells were seeded at 10 5 cells/ml in growth media and passaged 1 : 4 every 48 h to maintain cells in log phase growth. GFPtpz expression was monitored by flow cytometry as described above. For assessment of proliferation in whole-cell cultures, cells were seeded at 5 Â 10 4 cells/ml. Cell density was determined using a hemacytometer (five replicates per sample per time point). For methylcellulose colony assays, cells were suspended at 1000 cells/ml in 2% methylcellulose/RPMI supplemented with 15% FCS, 0.2 mM glutamine, 50 U/ml penicillin and 50 mg/ml streptomycin, and 1 ml was plated into 12-well plate wells. Colonies were counted after 8 days. Where required, G418-resistant cells were selected with 500 mg/ml G418.
Construction of retroviral vectors and retroviral gene transfer
Schematic illustrations of all of the retroviral vectors used in this study are provided in Figure 1 . Construction of the pL9IGFP and pL9NrIGFP plasmids was described previously (Dolnikov et al., 2003a) . The pLIB plasmid containing a leukocyte derived cDNA library with an approximate complexity of 3 Â 10 8 was purchased from Clontech. The pLIB-EGFP plasmid was constructed by cloning the EGFP gene from the pLEIN plasmid into the EcoRI site of the pLIB backbone (Clontech). The pLIRF2IN plasmid was generated by cloning the full-length IRF-2 cDNA (PCR amplified from the recovered IRF-2 cDNA using the forward primer 5 0 -ACA CCT CGA GGG CAC CAT GCC-3 0 and reverse primer 5 0 -GAG GAT CCG AGG CTT AAC AGC-3 0 ) into the XhoI and BamHI sites of pLXIN (Clontech). The pLtPIN vector was constructed by cloning the smaller of the two t-pp2135 cDNAs recovered from the library screen into the XhoI and BamHI sites of the pLXIN plasmid. PCR conditions: each reaction comprised 200 mM each dNTP, 3 mM MgCl 2 , 0.2 mM each primer, 2.5 U Amplitaq Gold, 1 ng DNA template; cycling conditions of 10 min, at 941C, then 30 cycles of 941C for 30 s, 641C for 30 s, 721C for 1 min.
Generation of the virus producer cell lines PG13/L9IGFP and PG13/L9NrIGFP and infection of target cells with retrovirus derived from stable PG13-based producer cells were described previously (Dolnikov et al., 2003a) . For transient virus generation, Amphopak-293 (Clontech) and C-Cre cells were calcium phosphate transfected by standard techniques (Sambrook et al., 1989) with the relevant retroviral vector plasmid. VCM was harvested 48 and 72 h after transfection, mixed with polybrene to a final concentration of 8 mg/ml and used to infect exponentially growing target cells overnight at 371C.
Recovery of cDNA inserts by PCR
Genomic DNA was extracted using the Qiagen Dneasy kit according to the Manufacturer's instructions. Nested PCR was performed using the primers: 5 0 -AGC CCT CAC TCC TTC TCT AG-3 0 (external forward), 5 0 -TCT AGG CGC CGG AAT TC-3 0 (internal forward), 5 0 -GCT TGC CAA ACC TAC AGG-3 0 (external reverse) and 5 0 -TTT ATT TTA TCG ATG TTT GGC-3 0 (internal reverse). Each reaction comprised 200 mM each dNTP, 3 mM MgCl 2 , 0.2 mM each primer, 2.5 U Amplitaq Gold, 1 mg DNA template; cycling conditions of IRF-2 inhibits N-ras-induced growth suppression T Passioura et al 10 min, at 941C, then 10 cycles of 941C for 30 s, 551C for 30 s, 721C for 30 s. A measure of 1 ml of each reaction was used as template for nesting PCR conditions as above with 30 cycles of amplification. For generation of an enriched library after the first round of screening, PCR product from above was digested with EcoRI/ClaI, or SalI/NotI and cloned into EcoRI/ClaI, or SalI/NotI sites, respectively, of the pLIB vector. After the second round of screening, cDNA inserts were recovered by PCR as described above and cloned into the pCR2.1-TOPO vector (InVitrogen) according to the manufacturer's instructions. These inserts were sequenced using the internal forward primer from above.
Northern analysis
Cellular RNA was extracted using TRIzol reagent (Gibco) according to the manufacturer's instructions. Total cellular RNA (10-15 mg) was separated on a formaldehyde gel and transferred to a nylon membrane. IRF-1, IRF-2 and b-actin probes were generated as described previously (Passioura et al., 2005) . The p21 CIP1/WAF1 and pml probe were generated by 15 cycles of liner amplification from cDNA fragments using specific primers. -AGG CAG AAG ATG TAG AGC Template sequences: pml -DraIII digest of the full-length L-type PML/RARa cDNA (2888 bp; containing PML exons 1-6 and RAR a exons 3-9) (gift of A Todd) (Kastner et al., 1992) , Template sequence for the p21 CIP1/WAF1 probe was generated by PCR using the reverse primer from above and the forward primer (5 0 -3 0 ): AGG GGA CAG CAG AGG AAG. Reaction conditions: 200 mM each dNTP, 3 mM MgCl 2 , 0.2 mM each primer, 2.5 U Amplitaq Gold, 1 mg pZLWAF1 (el-Deiry et al., 1993) ; cycling conditions of 10 min, at 941C, then 30 cycles of 941C for 30 s, 551C for 30 s.
Abbreviations AML, acute myeloid leukemia; EGFP, enhanced green fluorescent protein; FACS, fluorescence-activated cell sorting; GFPtpz, yellow-shifted green fluorescent protein 'topaz' variant; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; IRF-1, interferon regulatory factor-1; IRF-2, interferon regulatory factor-2; IRF-E, interferon regulatory factor element; ISRE, interferon-stimulated responsive element; NOD/SCID, nonobese diabetic/severe combined immunodeficient; VCM, virus containing media.
